Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Gains from Investment Securities: 2020-2024

  • Keros Therapeutics' Gains from Investment Securities was N/A to $5.7 million in Q3 2024 from the same period last year, while for Sep 2024 it was $22.5 million, marking a year-over-year change of. This contributed to the annual value of $5.7 million for FY2024, which is 328.77% up from last year.
  • Latest data reveals that Keros Therapeutics reported Gains from Investment Securities of $5.7 million as of Q3 2024, which was up 328.77% from $1.3 million recorded in Q1 2023.
  • Keros Therapeutics' Gains from Investment Securities' 5-year high stood at $15.4 million during Q4 2022, with a 5-year trough of -$755,000 in Q4 2021.
  • Moreover, its 3-year median value for Gains from Investment Securities was $3.5 million (2023), whereas its average is $5.6 million.
  • As far as peak fluctuations go, Keros Therapeutics' Gains from Investment Securities tumbled by 1,615.91% in 2021, and later spiked by 2,144.24% in 2022.
  • Quarterly analysis of 5 years shows Keros Therapeutics' Gains from Investment Securities stood at -$44,000 in 2020, then plummeted by 1,615.91% to -$755,000 in 2021, then skyrocketed by 2,144.24% to $15.4 million in 2022, then reached $1.3 million in 2023, then reached $5.7 million in 2024.
  • Its last three reported values are $5.7 million in Q3 2024, $1.3 million for Q1 2023, and $15.4 million during Q4 2022.